Tissue-specific inactivation of p53 tumor suppression in the mouse

Genes and Development

Volumn 10, Issue 7, 1996, Pages 826-835

  Bowman, Tammy ^a   Symonds, Holly ^a,b   Gu, Liya ^a,c   Yin, Chaoying ^a   Oren, Moshe ^d   Van Dyke, Terry ^e  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^e NONE

Author keywords

apoptosis; cancer; cell specificity; p53; transgenic mice

Indexed keywords

PROTEIN P53;

ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; GENE LOSS; GENE MAPPING; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TISSUE SPECIFICITY; TUMOR SUPPRESSOR GENE;

ANIMALIA; MUS MUSCULUS;

EID: 0029916320     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.10.7.826     Document Type: Article

References (44)

1. Chen, J. and T. Van Dyke. 1991. Uniform cell-autonomous tumorigenesis of the choroid plexus by papovavirus large T antigens. Mol Cell Biol. 11: 5968-5976.
2. Chen, J., G. Tobin, J.M. Pipas, and T.A. Van Dyke. 1992. T Antigen mutant activities in transgenic mice: Roles of p53 and pRB-binding in tumorigenesis of the choroid plexus. Oncogene 7: 1167-1175.
3. Clarke, A.R., C.A. Purdie, D.J. Harrison, R.G. Morris, C.C. Bird, M.L. Hooper, and A.H. Wyllie. 1993. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362: 849-852.
4. Coffmann, R.L. and I.L. Weissman. 1981. A monoclonal antibody that recognizes B cells and B cell precursors in mice. J. Exp. Med. 153: 269-279.
5. Costa, R.H. and D.R. Grayson. 1991. Site-directed mutagenesis of hepatocyte nuclear factor (HNF) binding sites in the mouse transthyretin (TTR) promoter reveal synergistic interactions with its enhancer region. Nucleic Acids Res. 19: 4139-4145.
6. Costa, R.H., D.R. Grayson, K.G. Xanthopoulos, and J.E. Darnell. 1988. A liver-specific DNA-binding protein recognizes multiple nucleotide sites in regulatory regions of transthyretin, alpha 1-antitrypsin, albumin, and simian virus 40 genes. Proc. Natl. Acad. Sci. 85: 3840-3844.
7. Donehower, L.A. and A. Bradley. 1993. The tumor suppressor p53. Biochem Biophys. Acta 1155: 181-205.
8. Donehower, L.A., M. Harvey, B.L. Slagle, M.J. McArthur, C.A.J. Montgomery, J.S. Butel, and A. Bradley. 1992. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 356: 215-221.
9. Gottlieb, E., R. Haffner, T. von Ruden, E. Wagner, and M. Oren. 1994. Down-regulation of wild-type p53 activity interfers with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J. 13: 1368-1374.
10. Greenblatt, M.S., W.P. Bennett, M Hollstein, and C.C. Harris. 1994. Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res. 54: 4855-4878.
11. Haffner, R. and M. Oren. 1995. Biochemical properties and biological effects of p53. Curr. Opin. Genet. Dev. 5(1): 84-94.
12. Harlow, E., L.V. Crawford, D.C. Pim, and N.M. Williamson. 1981. Monoclonal antibodies specific for simian virus 40 tumor antigens. J. Virol. 39: 861-869.
13. Harvey, M., M.J. McArthur, C.A. Montgomery, J.S. Butel, A. Bradley, and L.A. Donehower. 1993. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice. Nature Genet. 5(3): 225-229.
14. Harvey, M., H. Vogel, D. Morris, A. Bradley, A. Bernstein, and L.A. Donehower. 1995. A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. Nature Genet. 9: 305-311.
15. Hinds, P.W. and R.A. Weinberg. 1994. Tumor suppressor genes. Curr. Biol. 4: 135-141.
16. Hollstein, M., D. Sidransky, B. Vogelstein, and C.C. Harris. 1991. p53 mutations in human cancers. Science 253: 49-53.
17. Howes, K.A., N. Ransom, D.S. Papermaster, J.G.H. Lasudry, D.M. Albert, and J.J. Windle. 1994. Apoptosis or retinoblastoma: alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Genes & Dev. 8: 1300-1310.
18. Jacks, T., L. Remington, B. Williams, E. Scmitt, S. Halachmi, R. Bronson, and R. Weinberg. 1994. Tumor spectrum analysis in p53-mutant mice. Curr. Biol 4: 1-7.
19. Kastan, M.B., C.E. Canman, and C.J. Leonard. 1995. P53, cell cycle control and apoptosis: Implications for cancer. Cancer Metastasis Rev. 14: 3-15.
20. Lane, D.P. 1992. p53, guardian of the genome. Nature 358: 15-16.
21. Levine A.J. 1993. The tumor suppressor genes. Annu. Rev. Biochem. 62: 623-651.
22. Levine, A.J., J. Momand, and C.A. Finlay. 1991. The p53 tumour suppressor gene. Nature 351: 453-456.
23. Lowe, S.W., E.M. Schmitt, S.W. Smith, B.A. Osborne, and T. Jacks. 1993. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-849.
24. Milner, J., E.A. Medcalf, and A.C. Cook. 1991. The tumour suppressor p53: Analysis of wild type and mutant p53 complexes. Mol. Cell. Biol. 11: 12-19.
25. Morgenbesser, S., B. Williams, T. Jacks, and R. DePinho. 1994. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371: 72-74.
26. Pan, H and A E. Griep. 1994 Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: Implications for tumor suppressor gene function in development. Genes & Dev. 8: 1285-1299.
27. _. 1995. Temporally distinct patterns of p53-dependent and p53-independent apoptosis during mouse lens development. Genes & Dev. 9: 2157-2169.
28. Picksley, S.M. and D.P. Lane. 1994. p53 and Rb: Their cellular roles. Curr. Opin. Cell Biol. 6(6): 853-858.
29. Pipas, J.M., K.W. Peden, and D. Nathans. 1983. Mutational analysis of simian virus 40 T antigen: Isolation and characterization of mutants with deletions in the T-antigen gene Mol Cell. Biol. 3: 203-213.
30. Saenz-Robles, M T., H. Symonds, J. Chen, and T. Van Dyke. 1994. Induction versus progression of brain tumor development. Differential functions for the pRB- and p53-targeting domains of simian virus 40 T antigen. Mol. Cell. Biol. 14(41): 2686-2698.
31. Shaulian, E., A. Zauberman, D. Ginsberg, and M. Oren. 1992. Identification of a minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell. Biol. 12: 5581-5592.
32. Shaulian, E., I. Haviv, Y. Shaul, and M. Oren. 1995. Transcriptional repression by the C-terminal domain of p53. Oncogene 10(4): 671-680.
33. Stenger, J.E., G.A. Mayr, K. Mann, and P. Tegtmeyer. 1992. Formation of stable p53 homotetramers and multiples of tetramers. Mol. Carcinog. 5: 102-106.
34. Sturzbecher, H.W., R. Brain, C. Addison, K. Rudge, M. Remm, M. Gnmaldi, E. Keenan, and J.R. Jenkins. 1992. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7(8): 1513-1523.
35. Symonds, H.S., S.A. McCarthy, J. Chen, J.M. Pipas, and T. Van Dyke. 1993. Use of transgenic mice reveals cell-specific transformation by a simian virus 40 T-antigen amino-terminal mutant. Mol Cell. Biol. 13: 3255-3265.
36. Symonds, H., L. Krall, L. Remington, M. Saenz Robles, T. Jacks, and T. Van Dyke. 1994a. p53-Dependent apoptosis in vivo. Impact of p53 inactivation on tumorigenesis. Cold Spring Harbor Symp Quant. Biol. 59: 247-257.
37. Symonds, H., L. Krall, L. Remington, M. Saenz-Robles, S. Lowe, T. Jacks, and T. Van Dyke. 1994b. p53-Dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-711.
38. Unger, T., M.M. Nau, S. Segal, and J.D. Minna. 1992. p53: A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11: 1383-1390.
39. Unger, T., J.A. Mietz, M. Scheffner, C.L. Yee, and P.M. Howley. 1993. Functional domains of wild-type and mutant proteins involved in transcriptonal regulation, transdominant inhibition, and transformation suppression. Mol Cell Biol. 13: 5186-5194.
40. Wade Evans, A. and J.R Jenkins. 1985. Precise epitope mapping of the murine transformation-associated protein, p53. EMBO J. 4: 699-706.
41. Wang, P., M. Reed, Y. Wang, G. Mayr, J.E. Stenger, M.E. Anderson, J.F. Schwedes, and P. Tegtmeyer. 1994. p53 domains: Structure, oligomerization, and transformation. Mol. Cell. Biol. 14(8): 5182-5191.
42. Wu, H., M. Wade, L. Krall, J. Grisham, Y. Xiong, and T. Van Dyke. 1996. Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21, halts hepatocyte cell cycle progression, postnatal liver development, and regeneration. Genes &. Dev. 10: 245-260.
43. Yan, C., R.H. Costa, J.E. Darnell, J.D. Chen, and T.A. Van Dyke. 1990. Distinct positive and negative elements control the limited hepatocyte and choroid plexus expression of transthyretin in transgenic mice. EMBO J. 9: 869-878.
44. Zambetti, G. and A. Levine. 1993. A comparison of the biological activities of wild-type and mutant p53. FASEB J. 7: 855-865.